Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PALISADE BIO, INC.

(PALI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Palisade Bio : Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders

10/22/2021 | 08:01am EST

CARLSBAD, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications, announces today that an early exercise option has led to the acquisition of the Seneca asset NSI-189, a neurogenic compound which was part of Seneca Biopharma’s product portfolio at the time of the merger to form Palisade Bio and which is part of the Contingent Value Rights issued to the pre-merger Seneca shareholders. Prior to the merger (in December 2020) Seneca had exclusively out-licensed the NSI-189 program with a 3-year exercise option.

Under the terms of the agreement to acquire NSI-189, the purchaser will pay an upfront cash payment of approximately $400,000 with up to an additional $4.5 million contingent on certain clinical development milestones or a subsequent license or sale of the asset by the purchaser within a certain period.

About Palisade Bio.
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier. For more information, please go to www.palisadebio.com.

This communication contains “forward-looking” statements, including, without limitation, statements related to the potential for any future milestone payments under the asset acquisition agreement. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, related to the Company’s ability to advance its clinical programs and the uncertain and time-consuming regulatory approval process. Additional risks and uncertainties can be found in Palisade Bio’s (formerly known as Seneca Biopharma, Inc.) Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade’s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Palisade Bio Investor Relations Contact: 
Dawn Hofmeister
ir@palisadebio.com

Palisade Bio Media Relations Contact:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378


Primary Logo

Source: Palisade Bio, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about PALISADE BIO, INC.
11/23Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Inclu..
AQ
11/23PALISADE BIO, INC. : Change in Directors or Principal Officers, Submission of Matters to a..
AQ
11/15Palisade Bio Reports Third Quarter Financial Results
AQ
11/12PALISADE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
11/12Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
10/28PALISADE BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
10/22PALISADE BIO : Announces Sale of Seneca Asset NSI-189 for the treatment of Central Nervous..
PU
10/22PALISADE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/22PALISADE BIO : to Sell Neurogenic Compound Previously Part of Seneca Biopharma's Product R..
MT
10/22PALISADE BIO : Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous..
AQ
More news
Analyst Recommendations on PALISADE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -29,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,73x
Yield 2021 -
Capitalization 31,4 M 31,4 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 10
Free-Float 81,8%
Chart PALISADE BIO, INC.
Duration : Period :
Palisade Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALISADE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,31 $
Average target price 7,00 $
Spread / Average Target 203%
EPS Revisions
Managers and Directors
Thomas M. Hallam Chief Executive Officer & Director
J. D. Finley Chief Financial Officer
Ryker Willie Finance Director & Controller
James R. Neal Chairman
John Rodenrys Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
PALISADE BIO, INC.-56.25%31
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431